Skip to main content
SpringerLink
Log in

Neuroblastoma in adolescents: genetic and clinical characterisation

  • Research Articles
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

Age at diagnosis is an important risk factor in neuroblastoma (NB) with worse prognosis in children older than 18 months. A more indolent course with long-term relapses and fatal outcome has been described in small series of adolescents. Our objective was to describe biological factors that contribute to this particular behaviour and could be helpful in their treatment.

Procedure

NB cases older than 10 years of age at diagnosis registered in the files of the Neuroblastoma Group of SEOP from 1992 to 2007 were included. Disease extension was classified according to the International Neuroblastoma Staging System (INSS). Tumour samples were studied according to the International Neuroblastoma Pathology Classification (INPC). Biological studies included MNA, 1p, 11q and 17q status and ploidy.

Results

Twenty-two patients, from 10.1 to 24.6 years old, were included. Advanced stages predominated. 14/17 patients presented unfavourable histology. None had NMA or 1p del. However, 11q del was found in 8/13 cases and 17q gain in 7/11. Overall survival (OS) and event-free survival (EFS) for the entire series at 5 years were 0.45 and 0.32, respectively. Moreover, 5-year OS and EFS for stage 4 patients were 0.33 and 0.15.

Conclusions

NB in adolescents is a special subgroup characterised by high-risk prognostic features which differ from those seen in younger patients, especially in relation to genetic abnormalities. The outcome in stage 4 was worse than in younger metastatic children, outlining the need for new therapeutic approaches in this subgroup of patients. The exact cut-off to separate older patients has not yet been established and will probably be based on biology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brodeur GM, Maris JM (2002) Neuroblastoma. In: Pizzo PA, Poplack DG (eds) Principles and practice of paediatric oncology, 4th edn. JB Lippincott, Philadelphia, pp 895–938

    Google Scholar 

  2. Castel V, Canete A (2005) Tumores de la cresta neural. In: Madero L, Munoz A (eds) Hematologia y Oncologia Pediatrica, 2nd edn. Ergon, Madrid, pp 571–586

    Google Scholar 

  3. London WB, Castleberry RP, Matthay KK et al (2005) Evidence for an age cut-off greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol 23:6459–6465

    Article  CAS  PubMed  Google Scholar 

  4. Blatt J, Gula MJ, Orlando SJ et al (1995) Indolent course of advanced neuroblastoma in children older than 6 years at diagnosis. Cancer 76:890–894

    Article  CAS  PubMed  Google Scholar 

  5. Franks LM, Bollen A, Seeger RC et al (1997) Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 79:2028–2035

    Article  CAS  PubMed  Google Scholar 

  6. Kushner BH, Kramer K, Cheung NK (2002) Chronic neuroblastoma. Cancer 95:1366–1375

    Article  PubMed  Google Scholar 

  7. Brodeur GM, Pritchard J, Berthold F et al (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477

    CAS  PubMed  Google Scholar 

  8. Shimada H, Ambros IM, Dehner LP et al (1999) Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 86:349–363

    Article  CAS  PubMed  Google Scholar 

  9. Burgues O, Navarro S, Noguera R et al (2006) Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Arch 449:410–420

    Article  PubMed  Google Scholar 

  10. Ambros IM, Benard J, Boavida M et al (2003) Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21:2077–2084

    Article  CAS  PubMed  Google Scholar 

  11. Slater HR, Bruno DL, Ren H et al (2003) Rapid high throughput prenatal detection of aneuploidy using a novel quantitative method (MLPA). J Med Genet 40:907–912

    Article  CAS  PubMed  Google Scholar 

  12. Villamón E, Piqueras M, Mackintosh C et al (2008) Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma. Virchows Arch 453:47–55

    Article  PubMed  Google Scholar 

  13. Gaspar N, Hartmann O, Munzer C et al (2003) Neuroblastoma in adolescents. Cancer 98:349–355

    Article  PubMed  Google Scholar 

  14. Conte M, Parodi S, De Bernardi B et al (2006) Neuroblastoma in adolescents: the Italian experience. Cancer 106:1409–1417

    Article  CAS  PubMed  Google Scholar 

  15. Kushner BH, Kramer K, LaQuaglia MP et al (2003) Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol 41:508–515

    Article  PubMed  Google Scholar 

  16. Esiashvili N, Goodman M, Ward K et al (2007) Neuroblastoma in adults: incidence and survival analysis based on SEER data. Pediatr Blood Cancer 49:41–46

    Article  PubMed  Google Scholar 

  17. Castel V, Cañete A, Noguera R et al (2005) Neuroblastoma. Clin Transl Oncol 7:133–145

    Article  PubMed  Google Scholar 

  18. Attiyeh EF, London WB, Mossé YP et al; Children’s Oncology Group (2005) Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243–2253

    Article  CAS  PubMed  Google Scholar 

  19. Plantaz D, Vandesompele J, Van Roy N et al (2001) Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 91:680–686

    Article  CAS  PubMed  Google Scholar 

  20. Bown N, Lastowska M, Cotterill S et al; U.K. Cancer Cytogenetics Group and the U.K. Children’s Cancer Study Group (2001) 17q gain in neuroblastoma predicts adverse clinical outcome. Med Pediatr Oncol 36:14–19

    Article  CAS  PubMed  Google Scholar 

  21. Vandesompele J, Baudis M, De Preter K et al (2005) Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 23:2280–2299

    Article  CAS  PubMed  Google Scholar 

  22. Breen CJ, O’Meara A, McDermott M et al (2000) Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization. Cancer Genet Cytogenet 120:44–49

    Article  CAS  PubMed  Google Scholar 

  23. Wang Q, Diskin S, Rappaport E et al (2006) Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 66:6050–6062

    Article  CAS  PubMed  Google Scholar 

  24. Stallings RL, Yoon K, Kwek S, Kong D (2007) The origin of chromosome imbalances in neuroblastoma. Cancer Genet Cytogenet 176:28–34

    Article  CAS  PubMed  Google Scholar 

  25. Matthay KK, Villablanca JG, Seeger RC et al (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 341:1165–1173

    CAS  Google Scholar 

  26. Castel V, Cañete A, Navarro S et al (2001) Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol 37:537–542

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unidad de Oncología Pediátrica, Hospital Universitario La Fe, Avenida de Campanar, 21, ES-46009, Valencia, Spain

    Victoria Castel, Adela Cañete & Yania Yáñez

  2. Departamento de Patología Facultad de Medicina, Universidad de Valencia, Valencia, Spain

    Eva Villamón, Samuel Navarro, Amparo Ruiz & Rosa Noguera

  3. Unidad de Oncología Pediátrica, Hospital 12 de Octubre, Madrid, Spain

    Carmen Melero

  4. Unidad de Oncología Pediátrica, Hospital Carlos Haya, Málaga, Spain

    Antonio Herrero

Authors
  1. Victoria Castel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eva Villamón
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adela Cañete
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samuel Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amparo Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carmen Melero
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonio Herrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yania Yáñez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rosa Noguera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victoria Castel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castel, V., Villamón, E., Cañete, A. et al. Neuroblastoma in adolescents: genetic and clinical characterisation. Clin Transl Oncol 12, 49–54 (2010). https://doi.org/10.1007/s12094-010-0466-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-010-0466-z

Keywords

Search

Navigation